Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of saikoside compounds in preparation of drug for treating neurodegenerative diseases

A neurodegenerative and saikosaponin technology, applied in the field of medicine, can solve the problems of special parts, complex pathogenesis of ND, and lack of therapeutic drugs, etc., and achieve the effect of enhancing nest building ability, firm nest, and obvious protective effect

Active Publication Date: 2015-11-25
NINGXIA MEDICAL UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis and special location of ND, there is still a lack of effective therapeutic drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of saikoside compounds in preparation of drug for treating neurodegenerative diseases
  • Application of saikoside compounds in preparation of drug for treating neurodegenerative diseases
  • Application of saikoside compounds in preparation of drug for treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The statistical results of the effects of the saikosaponin series compounds of Example 1 and Example 2 on the release of microglial inflammatory factors NO and ROS are shown in Table 1;

[0033] Example 1: The effect of saikosaponin on LPS-induced NO release from microglial cells was investigated by Griess colorimetry;

[0034] Cell line: mouse microglial cell line BV-2;

[0035] Drugs: LPS; saikosaponin a; saikosaponin b1, b2, c, d; MINO.

[0036] method:

[0037] (1) Culture of mouse microglial cell line BV-2:

[0038] The cell culture solution was prepared based on DMEM medium, containing 10% FBS, 100 U penicillin and 100 U streptomycin, and 50 μM 2-mercaptoethanol (both final concentrations). at 5% CO 2 , under the condition of 37 ℃, the BV-2 microglial cells were divided into about 4×10 5 The cell density of cells / ml was cultured in a cell culture incubator, and the growth of the cells was observed regularly. When the area of ​​the cell adherence accounted for...

Embodiment 3

[0051] Embodiment 3: Novel Object Recognition (NovelObjectRecognition, NOR) experiment investigates the impact of saikosaponin a on the novel object discrimination ability of LPS-induced learning and memory impairment mice; the structure is as figure 1 Shown:

[0052] Material animal: ICR male mouse, 18-22g;

[0053] Drugs: LPS; saikosaponin a; donepezil hydrochloride;

[0054] Methods: ICR mice were randomly divided into 6 groups, 12 in each group: blank control group, model control (LPS) group, saikosaponin a high, medium and low dose group and positive control group (donepezil hydrochloride). Animals in each group were lightly anesthetized with chloral hydrate, fixed their heads, and injected into the lateral ventricle. Model group, saikosaponin a low dose (2 mg / kg) group, saikosaponin a medium dose (4 mg / kg) group, saikosaponin a high dose (8 mg / kg) group and positive control group (5 mg / kg) LPS solution (5 mg / ml, 3 μl / mouse) was injected, and mice in the blank control ...

Embodiment 4

[0057] Example 4: Y maze experiment to investigate the effect of saikosaponin a on the working memory ability of LPS-induced learning and memory impairment mice; the results are as follows figure 2 Shown:

[0058] Material animal: ICR male mouse, 18-22g;

[0059] Drugs: LPS; saikosaponin a;

[0060] Methods: ICR mice were randomly divided into 6 groups, 12 in each group: blank control group, model control (LPS) group, saikosaponin a high, medium and low dose group and positive control group (donepezil hydrochloride). Animals in each group were lightly anesthetized with chloral hydrate, fixed their heads, and injected into the lateral ventricle. Model group, saikosaponin a low dose (2 mg / kg) group, saikosaponin a medium dose (4 mg / kg) group, saikosaponin a high dose (8 mg / kg) group and positive control group (5 mg / kg) LPS solution (5 mgl / ml, 3 μl / mouse) was injected, and the mice in the blank control group were injected with an equal volume of normal saline. From the next ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of saikoside compounds in preparation of drug for treating neurodegenerative diseases. Five saikoside compounds are saikoside a, saikoside b1, saikoside b2, saikoside c and saikoside d which can remarkably inhibit release of LPS-induced microglial cell inflammation factors NO and ROS, and saikoside a can obviously shorten escape latency and escape distance of mice with LPS-induced learning memory impairment; in a nesting experiment, saikoside a can obviously enhance nesting ability of the mice with the LPS-induced mice with learning memory impairment. The above results show that saikoside a has obvious protecting effect on LPS-induced AD mouse learning memory impairment. Consequently, saikoside a, b1, b2, c and d can be used for treating the neurodegenerative diseases and inhibiting neuroinflammation.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of saikosaponins in the preparation of medicines for treating neurodegenerative diseases. Background technique [0002] Neurodegenerative diseases (neurodegenerationdisorders, ND) are a group of chronic progressive neurological diseases based on primary neuron degeneration, mainly including Alzheimer's disease (Alzheimer, sdisease, AD), Parkinson's disease (Parkinson's disease) sdisease, PD), multiple sclerosis (multiplesclerosis, MS), Huntington's disease (Huntington'sdisease, HD) and so on. Studies have found that ND is caused by a variety of different reasons, including insufficient nutrition provided by neurons or glial cells, neuroinflammation, impaired axonal transmission, hyperactivity of glutamate receptors, and excessive levels of reactive oxygen species. High, impaired metabolic pathways, decreased mitochondrial energy production and other ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K31/704A61P25/00
Inventor 李娟姚遥李玮琦孙娜水栋
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com